Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157887 | 1.00 | HDAC1 (0.41) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6156977 | 0.82 | KDM4E (0.60) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6156973 | 0.82 | KDM4E (0.60) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6878897 | 0.79 | HDAC1 (0.42) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6878892 | 0.79 | HDAC1 (0.42) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6852022 | 0.77 | HDAC1 (0.41) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6852028 | 0.77 | HDAC1 (0.41) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6852112 | 0.77 | CYP2A6 (0.56) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6851945 | 0.75 | HDAC1 (0.42) | HDAC1NPC1RAB9AKDM4EGLA | |
| SCHEMBL6851947 | 0.75 | HDAC1 (0.42) | HDAC1NPC1RAB9AKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933283-B2 | 11-deoxy azalide antibacterials | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | claimed |
| EP-1501847-A2 | 11-DEOXY AZALIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040014953-A1 | 11-Deoxy azalide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003090679-A2 | 11-DEOXY AZALIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | claimed |
| US-6933283-B2 | 11-deoxy azalide antibacterials | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1501847-A2 | 11-DEOXY AZALIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040014953-A1 | 11-Deoxy azalide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003090679-A2 | 11-DEOXY AZALIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014953-A1 | 11-Deoxy azalide antibacterials | TOP1, TOP2B, TOP2A | HDAC1 150/4885NPC1 1463/4885RAB9A 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.